High-Intensity Interval Training, Inflammatory Biomarkers, and Circulating MicroRNAs in Human Clinical Obesity.

November 16, 2026 updated by: Sofia Uribe-Cerda, Universidad Nacional Andres Bello

Effects of High-Intensity Interval Training on Body Composition, Inflammatory Biomarkers, and Circulating MyomiRs in Adults With Clinical Obesity: A Randomized Controlled Trial.

This randomized controlled trial evaluates the effects of high-intensity interval training (HIIT) on body composition, inflammatory biomarkers, and circulating microRNAs in adults with clinical obesity. Circulating microRNAs are small regulatory molecules that may reflect exercise-induced adaptations and inter-tissue communication related to skeletal muscle and metabolic health. The study investigates whether exercise-induced changes in adiposity are accompanied by changes in inflammatory status and circulating microRNA profiles associated with skeletal muscle adaptations and metabolic health.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Clinical obesity is characterized by excessive adiposity accompanied by impaired metabolic health and chronic low-grade inflammation. Emerging evidence suggests that obesity is also associated with alterations in circulating molecular biomarkers that may influence skeletal muscle function and inter-tissue communication.

High-intensity interval training (HIIT) is an effective exercise strategy for improving body composition and cardiometabolic health; however, the molecular mechanisms underlying these adaptations remain incompletely understood. In particular, limited information is available regarding the response of circulating muscle-related microRNAs (myomiRs) to exercise interventions in adults with clinical obesity.

This randomized controlled trial is designed to investigate physiological and molecular adaptations to HIIT in adults with clinical obesity. The study will examine the relationship between changes in adiposity, systemic inflammation, and circulating microRNA expression following a supervised exercise intervention. Circulating microRNAs may provide insight into exercise-responsive biological pathways and represent potential biomarkers of skeletal muscle adaptation and metabolic health.

The findings may improve understanding of the molecular mechanisms associated with exercise-induced health benefits in clinical obesity and contribute to the identification of novel biomarkers relevant to obesity management and precision exercise medicine.

Study Type

Interventional

Enrollment (Estimated)

17

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Metropolitan Region
      • Santiago, Metropolitan Region, Chile
        • Exercise and Rehabilitation Sciences Institute, School of Physical Therapy, Faculty of Rehabilitation Sciences, Universidad Andres Bello.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 39 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 20 to 39 years.
  • Clinical obesity defined primarily by body fat percentage (>29% in women and >20% in men), complemented by body mass index (BMI ≥30 kg/m²) and waist-to-height ratio (≥0.55).
  • Low habitual physical activity level, defined as not meeting the criteria for moderate or high physical activity according to the International Physical Activity Questionnaire-Short Form (IPAQ-SF).

Exclusion Criteria:

  • Cardiovascular disease.
  • Metabolic disease (e.g., type 2 diabetes mellitus or dyslipidemia).
  • Inflammatory or autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, or psoriasis).
  • Current smoking.
  • Chronic medication use that may affect metabolic or inflammatory outcomes.
  • Pregnancy and lactation.
  • Participation in a structured exercise program within the previous 6 months. Contraindications to high-intensity exercise.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High-Intensity Interval Training (HIIT)

Participants assigned to this arm will complete a supervised high-intensity interval training (HIIT) program performed on a cycle ergometer three times per week during 8 weeks. Each training session will last approximately 30 minutes and include a warm-up, high-intensity intervals performed at approximately 90% of maximal power output, active recovery periods, and a cool-down. All sessions will be supervised by qualified personnel to ensure participant safety and adherence to the protocol.

Participants will complete a supervised high-intensity interval training (HIIT) program performed on a cycle ergometer three times per week during eight weeks. Each session will last approximately 30 minutes and consist of a warm-up, ten 1-minute high-intensity intervals performed at approximately 90% of maximal power output, interspersed with 1-minute active recovery periods, and a cool-down. Training intensity will be reassessed midway through the intervention to ensure appropriate progression. All sessions will be supervised by qualified personnel to promote adherence, proper exercise execution, and participant safety.

No Intervention: Control

Participants assigned to this arm will maintain their habitual lifestyle without participating in a structured exercise program during the intervention period. Educational materials on healthy lifestyle habits will be provided at the end of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Body Fat Mass Assessed by Bioelectrical Impedance Analysis
Time Frame: Change from baseline to Week 8

Total body fat mass (kg) will be assessed using bioelectrical impedance analysis and compared between baseline and post-intervention measurements.

Change from baseline to Week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma Interleukin-1β (IL-1β) and Tumor Necrosis Factor-α (TNF-α) concentration Assessed by ELISA
Time Frame: From baseline to Week 8

Plasma IL-1β concentration (pg/mL) and TNF-α concentration (pg/mL) measured by enzyme-linked immunosorbent assay (ELISA).

From baseline to Week 8
Circulating Myo-MicroRNAs
Time Frame: from enrollment to the end of treatment at 8 weeks

Change in circulating expression of miR-1, miR-133, and miR-206 quantified by RT-qPCR.

from enrollment to the end of treatment at 8 weeks
Peak Oxygen Uptake (VO₂peak)
Time Frame: From baseline to Week 8

Change in cardiorespiratory fitness assessed by peak oxygen uptake during an incremental cycling test.

From baseline to Week 8
Handgrip Strength
Time Frame: From baseline to Week 8

Change in maximal handgrip strength assessed using a hydraulic hand dynamometer.

From baseline to Week 8
Maximal Voluntary Isometric Contraction (MVC)
Time Frame: From baseline to Week 8

Change in maximal isometric strength of the knee extensor muscles measured by dynamometry.

From baseline to Week 8
Health-Related Quality of Life Assessed Using the 36-Item Short Form Health Survey (SF-36)
Time Frame: From baseline to Week 8

Change in health-related quality of life assessed using the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better perceived health status and quality of life.

From baseline to Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

October 1, 2027

Study Registration Dates

First Submitted

October 29, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 64B2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.